stockrow
Friday 6 November 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
0.63
0.01
+1.61%
Follow LAB
Alert me
Standard BioTools Inc. (LAB) P/E ratio
As of 5 November 2026, Standard BioTools Inc. (LAB) trades at a P/E ratio of 1.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 6.4× (June 2026); the current reading is higher than 95% of that period. That is below the Medical Devices industry median of 25.6× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 2.1× | (42.34%) |
| Jun 2026 | 3.7× | (18.97%) |
| Mar 2026 | 4.6× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 6.4×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RXST RxSight, Inc. compare | n/m |
| STIM Neuronetics, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. compare | n/m |
| PROF Profound Medical compare | n/m |
| LAB Standard BioTools Inc. | 1.8× |
| ELMD Electromed, Inc. compare | 19.4× |
| INFU InfuSystems Holdings, Inc. compare | 32.0× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)